Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients

13Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood–brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.

Cite

CITATION STYLE

APA

Hafez, G., Malyszko, J., Golenia, A., Klimkowicz-Mrowiec, A., Ferreira, A. C., Arıcı, M., … Liabeuf, S. (2023, December 1). Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients. Clinical Kidney Journal. Oxford University Press. https://doi.org/10.1093/ckj/sfad239

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free